Project

The use of bio- adhesives with minimal scarring and easy to use after treatment is on the rise.

- Proceeding with overseas clinical trials

- Sale of bio-adhesive for animals and sale of bio-adhesive for wound treatment for human body

Project Summary

Our EG-Q showed excellent safety and regeneration performance and excellent tensile strength as a result of preclinical experiments on regeneration of cytotoxicity and wound tissue.

EG-Q has less toxicity than the world's top products.

Promote commercialization by securing price and quality competitiveness by acquiring core technology of its own (securing quality equal to or better than the world's top products)

Currently, we are actively collaborating with domestic customers, Chinese and US companies.

Business Model

- Sale of bio-adhesive for animals and sale of bio-adhesive for wound treatment for human body

Major Customers
: Livestock farmers, companion animal treatment hospitals, surgical hospitals, etc.

Main channel
: Direct sales through related institutions in domestic and overseas livestock related animal hospitals, companion animal care hospitals, sales through related companies in surgical hospitals, expansion of distribution channels through Amazon and large retail companies in the future

Overseas advance
: Coming to China, USA

Core Activities
: Proceeding with overseas clinical trials

Main Achievements

Job creation
: 6 persons (4 → 10)

Papers and patents
('13) Domestic registration 1 case
('15) Domestic registration 1 case
('16) USP registration 1 case
('17) Domestic registration 3 cases, trademark rights 5 cases
('18) Domestic registration 2 cases

Investment attraction
: Attracting 900 million(KRW) investment from KIBO( technology guarantee)

Etc
: Received an MOU with a number of foreign companies to enter the US and Chinese market.